Experiencia con el uso de la timoglobulina como terapia de inducción en el trasplante renal en el noroeste de México.

Research output: Contribution to journalArticlepeer-review


Introduction: Immunotherapy has been used for a long time to improve the survival of the renal graft. Thymoglobulin is one of the most used agents. In Mexico, there are few studies on this subject. Objective: To evaluate the success of the use of thymoglobulin as induction therapy and the complications observed in the first year after renal transplantation in a third level care center in northwestern Mexico. Material and methods: Simple and retrospective cross-sectional study in 160 patients transplanted from 2011 to 2016, in all cases thymoglobulin was used as induction therapy. From the clinical files, variables prior to transplantation and follow-up during the first year were reviewed. The information was analyzed with descriptive and inferential statistics. An odds ratio calculation was used to evaluate the risk of complications and failure in therapy. A value of p equal to or less than 0.05 was considered statistically significant. Results: The function of the transplanted graft was successful in 92% of the transplanted cases in relation to serum creatinine levels (p = 0.0001). Renal rejection during the first year occurred in 18% (OR = 0.37, p = 0.03), with the acute type being the most common in 14% (OR = 0.37, p = 0.04). The most common complications were infectious (OR = 0.82, p = 0.60). Discussion: Our results are consistent with that reported in the literature in relation to success in graft survival greater than 95% in those patients managed with thymoglobulin induction during the first year of follow-up.
Original languageSpanish (Mexico)
JournalRev Mex Traspl
StatePublished - 1 Jan 2019

Cite this